The present invention provides for a method of treating pulmonary disease
in a subject comprising the administration to a subject in need of such
treatment a therapeutically effective amount of a formulation comprising
a SP-C therapeutic. Preferably, the SP-C therapeutic is an agent selected
from the group consisting of an isolated SP-C protein, an isolated
nucleic acid molecule encoding a SP-C protein, a SP-C receptor-specific
antibody that stimulates the activity of the receptor, or
pharmaceutically acceptable composition thereof. The present invention
also provides methods of producing a mouse with a targeted disruption in
a surfactant protein C (SP-C) gene. The present invention also provides
for a transgenic mouse produced by a targeted disruption in a surfactant
protein C (SP-C) gene. The present invention further provides for a cell
or cell line from a transgenic mouse produced by a targeted disruption in
a surfactant protein C (SP-C) gene.
